By Fineline Cube 
Shanghai Innogen Pharmaceutical Technology Co., Ltd recently had its patent for efsubaglutide alfa (brand name: Yinuoqing) fully invalidated. The patent, titled “Composition and Method for Preventing and Treating Type I and Type II Diabetes” (Patent No.: 200680035546.4), was revoked due to insufficient experimental data to substantiate its claimed technical effects and fusion protein properties.
Drug and Patent Details
Efsubaglutide alfa is a next-generation ultra-long-acting glucagon-like peptide 1 (GLP-1) receptor agonist used to treat type 2 diabetes (T2D). It was approved in China in January this year for blood sugar control in type 2 diabetes.
Invalidation Ruling
The invalidation ruling allows the patent holder to appeal to the Beijing Intellectual Property Court within three months of receiving the notice.-Fineline Info & Tech